News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trimeris, Inc. (TRMS), Synageva BioPharma Set Date to Vote on Merger


10/13/2011 1:56:17 PM

Lee Weisbecker, Staff Writer - Triangle Business Journal

Durham-based Trimeris and its merger partner, Synageva BioPharma Corp. of Lexington, Mass., have set Nov. 2 as the date for their respective shareholders to vote on the deal.

Synageva, a privately held firm, develops various protein agents. Trimeris’ key product is the anti-HIV drug Fuzeon.

Synageva is buying Trimeris and, upon closing, the combined company will be named Synageva BioPharma Corp.

Trimeris (Nasdaq: TRMS) shareholders of record as of last Sept. 21 will be allowed to vote on the merger, which is an all-stock transaction valued at about $35 million. Trimeris shares currently trade in the $2.74 range, near the 52-week high of $2.96, according to Yahoo Finance.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES